I believe strongly in the benefits of clinical trials, which contributes to our knowledge about pulmonary hypertension and HHT, and advances the field. The medications we use in the clinic today are available because they were studied in past clinical trials and found to be effective. Our team strives to provide the very best clinical care, and to contribute to advancing new therapeutic options for the future.
Outside of the clinic, I am researching why pulmonary hypertension occurs and studying new ways to treat it. My lab studies one of the most common causes of pulmonary hypertension worldwide: the parasite schistosomiasis. Working with collaborators around the world, we are studying how the human immune system, in responding to this infection, also causes the side effect of altering blood vessels in the lung to result in pulmonary hypertension, and what treatment approaches we can use to block this effect.
Qualifications and experience
- Pulmonary Disease and Critical Care Medicine, Critical Care Medicine, Internal Medicine, Critical Care, Lungs and Breathing, Hereditary Hemorrhagic Telangiectasia (HHT), Lungs and Breathing - Pulmonary Hypertension
- Languages spoken
University of Colorado (University Hospital) Program (2010)
University of Colorado (University Hospital) Program (2005)
Harvard Medical School (2004)
University of Colorado (University Hospital) Program (2007)
Massachusetts Institute of Technology (MA) (2000)
Massachusetts Institute Of Technology (2000)
- Clinical interest for patients
After completing fellowship here at the University of Colorado I was privileged to join an exceptional team of doctors and nurses dedicated to the care of patients with pulmonary vascular disease. I am part of an outstanding team of caregivers who have earned a worldwide reputation for excellence in the field of pulmonary hypertension. I am also the medical director for our hereditary hemorrhagic telangiectasia (HHT, also known as Osler-Weber-Rendu) Center of Excellence at the University of Colorado Hospital.